Vikrant verma | Biology and Life Sciences | Research Excellence Award

Research Excellence Award

Vikrant Verma
Affiliation Swami Vivekanand Subharti University
Country India
Scopus ID 57213651680
Documents 20
Citations 70
h-index 4
Subject Area Biology and Life Sciences
Event International Soil Scientist Awards
ORCID 0000-0002-1994-9641

Vikrant Verma
Swami Vivekanand Subharti University,India

Vikrant Verma of Swami Vivekanand Subharti University is presented in connection with the Research Excellence Award at the International Soil Scientist Awards. His reported scholarly record comprises 20 documents, 70 citations, and an h-index of 4, with research classified within Biology and Life Sciences. The publication record supplied for this profile reflects interdisciplinary work spanning pharmacology, natural bioactive compounds, radiopharmaceuticals, neurobiology, and cardiovascular research.

Abstract

This academic recognition profile summarizes Vikrant Verma’s documented research activity and selected recent publications. The supplied works address mechanisms of bioactive compounds, Alzheimer’s disease, alkaloid pharmacology, targeted radiopharmaceuticals, gut-brain interactions, and endothelial dysfunction. Together, these publications indicate a research portfolio connecting molecular mechanisms with therapeutic and translational questions. The bibliometric information supplied for the profile records 20 documents, 70 citations, and an h-index of 4.

Keywords

Vikrant Verma; Research Excellence Award; Biology and Life Sciences; pharmacology; bioactive compounds; Alzheimer’s disease; molecular targets; radiopharmaceuticals; gut-brain axis; cardiovascular research.

Introduction

The supplied publication record demonstrates an interdisciplinary orientation within biomedical and life-science research. Recent work includes mechanistic reviews of traditional Chinese medicine-derived compounds and Mitragyna speciosa alkaloids, as well as research concerning PSMA-targeted radiopharmaceuticals and quercetin-mediated gut-brain interactions. These subjects involve molecular pharmacology, therapeutic development, safety considerations, and translational science.

Research Profile

The reported Scopus profile identifies 20 documents, 70 citations, and an h-index of 4. These metrics provide a quantitative snapshot of indexed scholarly output and citation activity and should be interpreted in relation to field, publication age, document type, and database coverage. [1]

Research Contributions

  • Analysis of molecular targets, standardization, and translational considerations for TCM-derived bioactive compounds in Alzheimer’s disease.
  • Examination of structure-activity relationships and safety profiles associated with Mitragyna speciosa alkaloids.
  • Review of PSMA-targeted radiopharmaceutical design and clinical translation.
  • Investigation of quercetin, microbiome modulation, and neuroprotective mechanisms involving the gut-brain axis.
  • Assessment of therapeutic strategies addressing endothelial dysfunction across cardiovascular and systemic diseases.

Publications

Selected publications supplied for this profile include the 2026 article on TCM-derived bioactive compounds in Pharmacological Research – Modern Chinese Medicine, the study of Mitragyna speciosa alkaloids in Current Bioactive Compounds, and work on PSMA-targeted radiopharmaceuticals in Current Radiopharmaceuticals. Additional publications address quercetin and the gut-brain axis and therapeutic strategies for endothelial dysfunction. [2] [3] [4]

Research Impact

The reported citation count and h-index document measurable scholarly visibility in indexed literature. The subject diversity of the selected publications also illustrates engagement with several areas of biomedical research, including neurodegeneration, natural-product pharmacology, molecular imaging, and vascular biology. Citation metrics are dynamic and may change as databases are updated. [1]

Award Suitability

The supplied record provides several documented elements relevant to an academic recognition profile: indexed publications, citation activity, an h-index, and recent research addressing contemporary questions in Biology and Life Sciences. The combination of mechanistic pharmacology, therapeutic investigation, and translational biomedical themes provides a substantive basis for consideration under a research-excellence framework, subject to the award’s formal evaluation criteria and verification procedures.

Conclusion

Vikrant Verma’s supplied academic profile reflects research activity in Biology and Life Sciences with publications covering molecular pharmacology and several translational biomedical themes. The reported Scopus metrics and selected 2026 publications provide measurable and recent indicators of scholarly activity. Continued publication, citation development, and interdisciplinary research may further document the evolution of this research profile.

References

  1. Elsevier. (n.d.). Scopus author details: Vikrant Verma, Author ID 57213651680. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57213651680
  2. Verma, V. (2026). Mechanistic pharmacology of TCM-derived bioactive compounds in Alzheimer’s disease: molecular targets, standardization, and translational insights. Pharmacological Research – Modern Chinese Medicine. DOI: 10.1016/j.prmcm.2026.100831
  3. Verma, V. (2026). Mechanistic Insights, Structure-activity Relationships, and Safety Profile of Mitragyna speciosa Alkaloids. Current Bioactive Compounds. DOI: 10.2174/0115734072492003260811045218
  4. Verma, V. (2026). Theranostic applications of PSMA-targeted radiopharmaceuticals: From molecular design to clinical translation and emerging paradigms. Current Radiopharmaceuticals. DOI: 10.1016/j.craph.2026.100054
  5. Verma, V. (2026). Quercetin and the gut-brain axis: Microbiome modulation, neuroprotection, and therapeutic implications. AIMS Molecular Science. DOI: 10.3934/molsci.2026012
  6. Verma, V. (2026). Therapeutic Strategies for Endothelial Dysfunction in Cardiovascular Disease, Rheumatoid Arthritis, and Diabetes: Current and Emerging Approaches. Cardiovascular & Hematological Agents in Medicinal Chemistry. DOI: 10.2174/0118715257414596251206101856

Irina Kumukova | Biology | Best Researcher Award

Assist. Prof. Dr. Irina Kumukova | Biology | Best Researcher Award

Ministry of Health of Russian Federation | Russia

Dr. Irina Kumukova, PhD, is a distinguished researcher specializing in haematology and blood transfusion, with a strong academic and professional record in transfusiology and pediatric hematology. She has authored 16 scientific documents indexed in Scopus, which together have received 42 citations across 29 documents, demonstrating both her scholarly productivity and the growing impact of her research. Her h-index of 4 reflects a meaningful contribution to advancing knowledge in transfusion medicine, extracorporeal photopheresis, and pathogen reduction strategies. Dr. Kumukova’s publications include pioneering clinical studies such as standard extracorporeal photopheresis for graft-versus-host disease treatment, innovative approaches to pathogen-reduced red blood cell suspensions, and novel methods addressing transfusion safety in children with oncological and hematological disorders. In addition, she has co-authored influential work on granulocyte transfusion, photopheresis case studies, and pathogen inactivation methods, which have shaped new perspectives in transfusion practice. Her role as Associate Professor and Head of the Transfusion Department underscores her leadership in bridging research with clinical practice. Furthermore, her patent on low-volume extracorporeal photochemotherapy exemplifies her ability to translate scientific innovation into applied medical solutions. Collectively, her academic achievements, clinical leadership, and consistent research productivity establish Dr. Kumukova as a promising contributor to the global scientific community.

Profile:  Scopus 

Featured Publications

“Transfusions of pathogen-reduced components of donor blood to recipients of allogeneic hematopoietic stem cell transplantation”